Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 4 | 2020 | 255 | 1.190 |
Why?
|
| Patient Selection | 2 | 2019 | 682 | 1.000 |
Why?
|
| Biomarkers | 3 | 2020 | 1755 | 0.990 |
Why?
|
| Macrophages | 3 | 2019 | 571 | 0.890 |
Why?
|
| Spironolactone | 1 | 2021 | 12 | 0.780 |
Why?
|
| Troponin T | 1 | 2020 | 39 | 0.730 |
Why?
|
| Monocytes | 2 | 2019 | 218 | 0.720 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2019 | 65 | 0.660 |
Why?
|
| Cytoskeleton | 4 | 2012 | 195 | 0.660 |
Why?
|
| Eligibility Determination | 1 | 2018 | 36 | 0.640 |
Why?
|
| Hypercholesterolemia | 1 | 2019 | 159 | 0.610 |
Why?
|
| Cardiology | 1 | 2019 | 115 | 0.600 |
Why?
|
| Heart Failure | 3 | 2021 | 1180 | 0.590 |
Why?
|
| Catheter Ablation | 1 | 2019 | 252 | 0.560 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 249 | 0.550 |
Why?
|
| Anticoagulants | 1 | 2019 | 426 | 0.530 |
Why?
|
| Psoriasis | 1 | 2019 | 245 | 0.530 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 433 | 0.530 |
Why?
|
| Connective Tissue Diseases | 1 | 2016 | 70 | 0.500 |
Why?
|
| Risk Assessment | 2 | 2020 | 2290 | 0.500 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 833 | 0.490 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 350 | 0.490 |
Why?
|
| Blood Pressure | 1 | 2018 | 899 | 0.480 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 362 | 0.480 |
Why?
|
| Inferior Wall Myocardial Infarction | 1 | 2012 | 2 | 0.430 |
Why?
|
| Heart Aneurysm | 1 | 2012 | 22 | 0.430 |
Why?
|
| Hypertension | 1 | 2018 | 741 | 0.430 |
Why?
|
| Receptors, Immunologic | 1 | 2012 | 135 | 0.400 |
Why?
|
| Integrin beta1 | 3 | 2009 | 33 | 0.390 |
Why?
|
| Integrins | 4 | 2012 | 78 | 0.360 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 387 | 0.360 |
Why?
|
| Stress, Mechanical | 2 | 2009 | 253 | 0.350 |
Why?
|
| Membrane Proteins | 3 | 2013 | 1215 | 0.340 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2009 | 4 | 0.330 |
Why?
|
| Signal Transduction | 5 | 2012 | 3373 | 0.320 |
Why?
|
| Heart Ventricles | 2 | 2021 | 779 | 0.320 |
Why?
|
| Mechanotransduction, Cellular | 3 | 2009 | 80 | 0.320 |
Why?
|
| Nutrition Surveys | 2 | 2019 | 109 | 0.310 |
Why?
|
| Risk Factors | 4 | 2020 | 5466 | 0.310 |
Why?
|
| Actin Cytoskeleton | 2 | 2012 | 196 | 0.300 |
Why?
|
| Humans | 22 | 2021 | 89063 | 0.300 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2013 | 127 | 0.300 |
Why?
|
| Cholesterol | 2 | 2019 | 357 | 0.280 |
Why?
|
| Cells, Cultured | 6 | 2020 | 2880 | 0.240 |
Why?
|
| Microtubules | 1 | 2004 | 123 | 0.230 |
Why?
|
| Cell Membrane | 2 | 2013 | 668 | 0.230 |
Why?
|
| Heart-Assist Devices | 2 | 2021 | 756 | 0.230 |
Why?
|
| Prevalence | 2 | 2019 | 1240 | 0.220 |
Why?
|
| Calcium | 3 | 2006 | 1172 | 0.220 |
Why?
|
| Treatment Outcome | 3 | 2021 | 8203 | 0.210 |
Why?
|
| Age Factors | 2 | 2018 | 1867 | 0.210 |
Why?
|
| Middle Aged | 6 | 2021 | 25863 | 0.210 |
Why?
|
| Aged | 5 | 2021 | 19077 | 0.210 |
Why?
|
| Male | 8 | 2021 | 42251 | 0.210 |
Why?
|
| Magnetics | 2 | 2004 | 41 | 0.200 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2021 | 17 | 0.200 |
Why?
|
| Actins | 1 | 2004 | 458 | 0.190 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2020 | 5 | 0.190 |
Why?
|
| Vinculin | 1 | 2000 | 9 | 0.190 |
Why?
|
| Tetralogy of Fallot | 1 | 2021 | 44 | 0.190 |
Why?
|
| Cilia | 3 | 2006 | 29 | 0.180 |
Why?
|
| Female | 8 | 2021 | 46011 | 0.180 |
Why?
|
| Epithelial Cells | 1 | 2004 | 688 | 0.180 |
Why?
|
| Gene Silencing | 1 | 2020 | 178 | 0.180 |
Why?
|
| Kidney | 2 | 2004 | 1145 | 0.180 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 153 | 0.170 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 83 | 0.170 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 2014 | 0.170 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2021 | 136 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 1715 | 0.170 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2019 | 67 | 0.160 |
Why?
|
| Electrocardiography | 1 | 2021 | 493 | 0.160 |
Why?
|
| Stroke Volume | 1 | 2021 | 462 | 0.160 |
Why?
|
| American Heart Association | 1 | 2019 | 94 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 322 | 0.150 |
Why?
|
| Creatinine | 1 | 2018 | 293 | 0.150 |
Why?
|
| Antigens, CD | 1 | 2019 | 466 | 0.150 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 603 | 0.150 |
Why?
|
| NF-kappa B | 1 | 2020 | 465 | 0.140 |
Why?
|
| TRPP Cation Channels | 3 | 2006 | 17 | 0.140 |
Why?
|
| Health Status | 1 | 2018 | 370 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 280 | 0.130 |
Why?
|
| Prognosis | 2 | 2021 | 3773 | 0.130 |
Why?
|
| Focal Adhesions | 2 | 2009 | 70 | 0.130 |
Why?
|
| United States | 2 | 2019 | 6955 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2020 | 9003 | 0.130 |
Why?
|
| Young Adult | 2 | 2019 | 6288 | 0.130 |
Why?
|
| Animals | 11 | 2020 | 27317 | 0.130 |
Why?
|
| Heart Transplantation | 1 | 2021 | 716 | 0.130 |
Why?
|
| Cattle | 3 | 2012 | 375 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2018 | 771 | 0.120 |
Why?
|
| Comorbidity | 1 | 2018 | 948 | 0.120 |
Why?
|
| Adolescent | 2 | 2019 | 9237 | 0.120 |
Why?
|
| Blood Glucose | 1 | 2018 | 836 | 0.120 |
Why?
|
| Chemokine CCL2 | 1 | 2014 | 47 | 0.120 |
Why?
|
| Cyclic AMP | 2 | 2009 | 274 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 771 | 0.120 |
Why?
|
| Adult | 3 | 2019 | 26507 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 849 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1149 | 0.110 |
Why?
|
| Mice | 7 | 2020 | 11737 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1837 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 988 | 0.110 |
Why?
|
| Anion Exchange Protein 1, Erythrocyte | 1 | 2013 | 14 | 0.110 |
Why?
|
| Aquaporins | 1 | 2013 | 13 | 0.110 |
Why?
|
| Blood Cells | 1 | 2013 | 33 | 0.110 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2012 | 7 | 0.110 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 2 | 2006 | 141 | 0.110 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2012 | 18 | 0.110 |
Why?
|
| Polymerization | 1 | 2012 | 32 | 0.110 |
Why?
|
| Complement System Proteins | 1 | 2013 | 83 | 0.110 |
Why?
|
| Syncope | 1 | 2012 | 34 | 0.100 |
Why?
|
| Sex Factors | 1 | 2016 | 1063 | 0.100 |
Why?
|
| Chemotaxis | 1 | 2012 | 73 | 0.100 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2012 | 101 | 0.100 |
Why?
|
| Dyspnea | 1 | 2012 | 75 | 0.100 |
Why?
|
| Lipid Bilayers | 1 | 2013 | 136 | 0.100 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 262 | 0.100 |
Why?
|
| Endothelium, Vascular | 3 | 2009 | 433 | 0.090 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2013 | 255 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 740 | 0.090 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2012 | 192 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1706 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2012 | 638 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2018 | 4273 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 6777 | 0.090 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2009 | 128 | 0.080 |
Why?
|
| Mice, Knockout | 3 | 2020 | 1990 | 0.070 |
Why?
|
| Models, Biological | 2 | 2012 | 1763 | 0.070 |
Why?
|
| Aorta | 1 | 2009 | 288 | 0.070 |
Why?
|
| Epithelium | 2 | 2006 | 325 | 0.070 |
Why?
|
| Nocodazole | 1 | 2004 | 18 | 0.060 |
Why?
|
| Microspheres | 2 | 2004 | 108 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 1 | 2004 | 121 | 0.060 |
Why?
|
| Neurons | 1 | 2013 | 1580 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2004 | 284 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2004 | 426 | 0.060 |
Why?
|
| Extracellular Matrix | 1 | 2004 | 244 | 0.050 |
Why?
|
| Atrial Pressure | 1 | 2021 | 6 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2021 | 156 | 0.050 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 25 | 0.050 |
Why?
|
| Cholesterol, Dietary | 1 | 2020 | 27 | 0.050 |
Why?
|
| Diastole | 1 | 2021 | 141 | 0.050 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2020 | 68 | 0.050 |
Why?
|
| Homeostasis | 1 | 2003 | 413 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2021 | 113 | 0.050 |
Why?
|
| Calibration | 1 | 2000 | 104 | 0.050 |
Why?
|
| Allografts | 1 | 2021 | 181 | 0.040 |
Why?
|
| Ventricular Function, Right | 1 | 2021 | 146 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2000 | 289 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 319 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 1057 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2021 | 490 | 0.040 |
Why?
|
| Proteins | 1 | 2003 | 786 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1855 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1310 | 0.030 |
Why?
|
| Echocardiography | 1 | 2021 | 937 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2000 | 1157 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2021 | 1064 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 971 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2014 | 34 | 0.030 |
Why?
|
| Micelles | 1 | 2014 | 48 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2752 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2014 | 34 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 105 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 293 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2014 | 130 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 3209 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 2411 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 1012 | 0.030 |
Why?
|
| Binding Sites | 1 | 2014 | 1117 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 2062 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 1574 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 3027 | 0.020 |
Why?
|
| Child | 1 | 2021 | 7149 | 0.020 |
Why?
|
| Biophysical Phenomena | 1 | 2004 | 124 | 0.010 |
Why?
|
| Biophysics | 1 | 2004 | 153 | 0.010 |
Why?
|
| Capillaries | 1 | 2004 | 90 | 0.010 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2003 | 25 | 0.010 |
Why?
|
| Mutation | 2 | 2006 | 4132 | 0.010 |
Why?
|
| Tubulin | 1 | 2003 | 59 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2004 | 188 | 0.010 |
Why?
|
| Ligands | 1 | 2004 | 443 | 0.010 |
Why?
|
| Temperature | 1 | 2004 | 400 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 2003 | 145 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 2327 | 0.010 |
Why?
|
| Caffeine | 1 | 2003 | 83 | 0.010 |
Why?
|
| Heterozygote | 1 | 2003 | 373 | 0.010 |
Why?
|
| Calcium Channels | 1 | 2003 | 182 | 0.010 |
Why?
|
| Protein Transport | 1 | 2003 | 421 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2004 | 459 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2000 | 97 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2000 | 68 | 0.010 |
Why?
|
| Physical Stimulation | 1 | 2000 | 72 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2000 | 108 | 0.010 |
Why?
|
| DNA | 1 | 2006 | 1307 | 0.010 |
Why?
|
| Protein Binding | 1 | 2003 | 1487 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 5320 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2000 | 1975 | 0.010 |
Why?
|